Evans, David S.; Salinger, Michael

Working Paper
An empirical analysis of bundling and tying: over-the-counter pain relief and cold medicines

CESifo Working Paper, No. 1297

Provided in Cooperation with:
Ifo Institute – Leibniz Institute for Economic Research at the University of Munich

Suggested Citation: Evans, David S.; Salinger, Michael (2004): An empirical analysis of bundling and tying: over-the-counter pain relief and cold medicines, CESifo Working Paper, No. 1297, Center for Economic Studies and Ifo Institute (CESifo), Munich

This Version is available at:
http://hdl.handle.net/10419/18935

Terms of use:
Documents in EconStor may be saved and copied for your personal and scholarly purposes. You are not to copy documents for public or commercial purposes, to exhibit the documents publicly, to make them publicly available on the internet, or to distribute or otherwise use the documents in public.

If the documents have been made available under an Open Content Licence (especially Creative Commons Licences), you may exercise further usage rights as specified in the indicated licence.
AN EMPIRICAL ANALYSIS OF BUNDLING AND TYING: OVER-THE-COUNTER PAIN RELIEF AND COLD MEDICINES

DAVID S. EVANS
MICHAEL SALINGER

CESifo Working Paper No. 1297
Category 9: Industrial Organisation
October 2004

Presented at CESifo Venice Summer Institute, workshop on recent developments in antitrust analysis, July 2004

An electronic version of the paper may be downloaded
• from the SSRN website: www.SSRN.com
• from the CESifo website: www.CESifo.de
AN EMPIRICAL ANALYSIS OF BUNDLING AND TYING: OVER-THE-COUNTER PAIN RELIEF AND COLD MEDICINES

Abstract

We apply and extend the cost-based approach to bundling and tying under competition developed in Evans and Salinger (2004a) to over-the-counter pain relievers and cold medicines. We document that consumers pay much less for tablets with multiple ingredients than they would to buy tablets with each ingredient separately. We then decompose the sources of these savings into marginal cost savings and a component that reflects fixed costs of product offerings. The analysis both documents substantial economies of bundling and illustrates the sort of cost analysis that is necessary for understanding tying.

JEL Code: L11.

David S. Evans  
LECG  
350 Massachusetts Avenue  
Suite 300  
Cambridge, MA 02139  
USA  
david_evans@lecg.com

Michael Salinger  
Boston University  
School of Management  
595 Commonwealth Ave.  
Boston, MA 02215  
USA  
salinger@bu.edu

The authors thank Irina Danilkina, Chris Nosko, and Ori Stitelman for exceptional research support and Tim Bresnahan, Howard Chang, Georg Getz, Nick Nichols, Bernard Reddy and Richard Schmalensee for comments and suggestions. Microsoft Corporation provided research funding for which the authors are grateful. The opinions expressed herein are those of the authors alone.
An Empirical Analysis of Bundling and Tying: Over-the-Counter Pain Relief and Cold Medicines

David S. Evans
Michael Salinger
August 2004

I. Introduction

At virtually any pharmacy, grocery store, or convenience store, one can purchase “cold tablets” that contain more than one active ingredient. The main components of these medicines are pain relievers, decongestants, antihistamines, and cough suppressants. Tablets (or other dosage forms) containing just one of the ingredients are also available. The tablets that contain more than one active ingredient are therefore examples of bundled products.¹ In this paper, we establish that the bundle discount is substantial and use a cost-based framework to estimate the cost savings from bundled products.

Our theoretical framework is based on the cost-based, unified theory of bundling and tying developed in Evans and Salinger (2004a). Under that theory, a bundle discount can be the result of two distinct cost effects. One is marginal cost savings (that could arise from, for example, conserving on the number of packages and tablets produced). The other is a reduction in the contribution to fixed costs of each product offering (such as the cost of a shelf slot or the system cost of an additional stock keeping unit). As we will explain,² whether the private savings consumers get from the bundle reflect social savings as well depends on the relative contribution of each. Thus, to estimate cost savings from bundling, we must empirically identify these two effects.

¹ A bundled product is one that combines more than one product that could be sold separately.
To do so, we exploit regularities in the pricing of different package sizes. The price per tablet for any given medication tends to be a decreasing function of package size.\(^3\) Suppose, for example, that a particular medicine—acetaminophen—is available in packages of 50, 100, and 200 tablets, with the price per tablet a decreasing function of tablet size. There seems no reason to rule out the possibility that some customers would ideally like to purchase 150 tablets. Such a customer could either buy one package of 100 tablets and one of 50 tablets, thus sacrificing potential economies of package size, or one package of 200 tablets that contains 50 more tablets than he wants. We estimate how high fixed costs would have to be to make it unprofitable to offer package sizes that we do not observe. As a basis for these estimates, we extend the model in Evans and Salinger (2004a) to package-size effects.

We estimate that, in this case, the marginal cost savings from bundled products exceed the fixed costs of the product offerings, so bundling lowers costs. For example, we estimate that the price of a package of 48 tablets that combines two active ingredients is $3.60 less\(^4\) than the sum of the prices of the same ingredients sold in separate packages of 48 tablets each. We decompose this $3.60 into a marginal cost savings of $2.40 and an average fixed cost of $1.20. The net cost effect is the difference between the two, or $1.20. The gain would be substantially larger for tablets that contain three active ingredients. Moreover, these cost effects do not capture the value of the convenience consumers get from bundled products.

\(^2\) See Section III.
\(^3\) While this assertion should come as no surprise, we document the regularity in Section II.
\(^4\) The percentage difference would vary with the active ingredients but would generally be between 30 percent and 50 percent.
We can also use our framework to estimate the cost savings from having the separate products available rather than having consumers who want just one component buy the bundled product. This type of calculation is important for addressing the policy issues associated with the antitrust laws concerning tying. Tying occurs when a bundled product is offered and at least one of the separate products is not. Since tying can be an antitrust violation, the law encourages companies, at least those with market power, to offer the products that it bundles separately as well. For a consumer who wants just one component of a bundle, buying the separate component rather than the bundle saves the marginal cost of the components he does not want. However, the separate component is itself a distinct product that generates a fixed cost of offering it. Selling the separate component only saves costs if the fixed cost is less than marginal costs avoided by not providing a customer with the part of a bundle he does not want. While in most of the cases we consider, our estimates are that the separate products save costs, there is one case in which we estimate that it does not. Of course, this result does not imply that the separate product should not be offered in this case. In the example we consider, consumers who want, for example, just pain relief, would strictly prefer not to have to take a decongestant at the same time. Just as a complete welfare analysis of bundling and tying would have to account for the convenience value of the bundle for consumers who want all the components, so would it also have to account for the possibility that some consumers would pay not to have a component of a bundle.

The remainder of the paper is organized as follows. Section II describes the data and establishes some broad empirical regularities in it. Section III describes our framework for understanding bundling and tying, applies it to the bundle discount, and
derives the formulas to calculate the (possibly negative) cost savings from the bundle and from the separate products. In Section IV, we extend the cost-based theory to package-size effects and derive the formula to calculate the average fixed cost of a good. We then estimate the average fixed costs and use them to in turn estimate the effect of bundling and components sales on costs. The concluding section provides a brief summary.

II. The Pricing of Pain Relief, Cold, Sinus, and Allergy Medicines

The primary data collected for this paper were the prices of all cold and pain relief medications sold at the Walgreens at 757 N. Michigan Ave. in Chicago on April 3, 2003. For each package, we observe the brand, the price, dosage form, quantity of each active ingredient per unit, and number of units. We have supplemented the data with some prices offered at the website of CVS and have generally checked prices on the web and at other outlets to confirm that the regularities we document are not specific to this particular location and time.

A. Empirical Regularities

We will ultimately use a price regression to describe the bundle discount. To guide the specification of that regression, it will be useful to explore less formally some strong regularities that are present in the data. We will also use these stylized facts to argue for a cost-based explanation for the bundle discount.

---

5 We use the term “cold” to include medications labeled as sinus, allergy, and cough as well.
6 Walgreens is a large pharmacy chain in the United States.
7 Dosage forms include tablets, caplets, liquid, “gel tabs,” etc.
8 The website www.cvs.com is a vehicle for ordering pharmaceuticals (and other products) to be delivered by mail. The website is operated by CVS, which also operates a large chain of retail pharmacies.
1. Bundle Discounts and Brand Name Premia

Johnson & Johnson’s Tylenol is the dominant brand of the pain reliever acetaminophen and Pfizer’s Sudafed is the dominant brand of the decongestant pseudoephedrine hydrochloride. Each Extra Strength Tylenol contains 500 mg of acetaminophen and each Maximum Strength Sudafed contains 30 mg of pseudoephedrine hydrochloride. Johnson & Johnson does not offer a Tylenol-brand pseudoephedrine hydrochloride nor does Pfizer offer a Sudafed-brand acetaminophen. However, both a Tylenol Sinus Caplet and a Sudafed Sinus and Headache Caplet contain 30 mg of pseudoephedrine hydrochloride and 500 mg of acetaminophen.\(^9\) Table 1 lists the prices we observed for 24-tablet packages of these products and for their store-brand equivalents.\(^{10}\) Table 1 illustrates two general phenomena in the pricing of this class of product. First, branded products command a substantial premium—from just over 30 percent to 50 percent—over the price of the CVS product. Second, within both the branded and non-branded segments, the price of the combination product is much lower than the sum of the prices of the stand-alone products. The incremental cost to a consumer of the pseudoephedrine hydrochloride in the Tylenol Sinus Caplet over purchasing just Extra Strength Tylenol is $2.00, which is only 44 percent of the price of buying a package of 24 Sudafed tablets. The incremental price of the acetaminophen in the Sudafed Sinus and Headache Caplets is $1.40, which is 35 percent of the price of buying a package of 24 Extra Strength Tylenol tablets. The comparisons are even more

---

\(^9\) Novartis also offers a product that contains 500 mg of acetaminophen and 30 mg of pseudoephedrine hydrochloride, Tavist Allergy/Sinus/Headache.

\(^{10}\) These data are taken from www.cvs.com rather than our Walgreens data set. To isolate the bundle discount, we need to hold package size constant. To do so, we need all six of the products in Table 1 (just acetaminophen, just pseudoephedrine, and the combination tablet in branded and generic form) available in
striking with the CVS products. The incremental price of the acetaminophen in the
combination product over pseudoephedrine hydrochloride tablets is only $0.50, or 17
percent of the price of buying acetaminophen tablets separately.\(^{11}\)

### Table 1. Prices for 24 Tablet/Caplet Packages

<table>
<thead>
<tr>
<th>Brand</th>
<th>Combination</th>
<th>Pseudoephedrine HCl Alone</th>
<th>Acetaminophen Alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tylenol</td>
<td>$5.99</td>
<td>NA</td>
<td>$3.99</td>
</tr>
<tr>
<td>Sudafed</td>
<td>$5.99</td>
<td>$4.59</td>
<td>NA</td>
</tr>
<tr>
<td>CVS</td>
<td>$3.99</td>
<td>$3.49</td>
<td>$2.99</td>
</tr>
</tbody>
</table>

Note: Tylenol: “Tylenol Sinus Caplet” (the combination product) and “Tylenol Extra Strength Caplets.”
Sudafed: “Sudafed Sinus and Headache Caplet” (the combination product) and “Sudafed Sinus & Cold.”
CVS: “Non-Aspirin Sinus Caplets Maximum Strength” (the combination product), “Nasal Decongestant Tablets Maximum Strength,” and “Non-Aspirin Caplets Extra Strength.” NA denotes a combination that
was not offered. Doses are 30 mg of pseudoephedrine hydrochloride and 500 mg of acetaminophen.


There are also products that combine pseudoephedrine hydrochloride and ibuprofen.

Here, the comparisons are not quite as clean because we observed package sizes of 20 rather
than 24 for the combination product. Still, as we will document in section II.A.3 below (and
as is well known), the price per pill is generally a decreasing function of package size. Thus,
comparing the price per pill of the bundled product with the sum of the prices per pill of the
component products sold in somewhat larger packages understates the gains from bundling.

We observed a price of $6.29 for a package of 20 Advil “Cold & Sinus” tablets, which is
less than $0.32/tablet. To buy Advil and Maximum Strength Sudafed separately in 24-tablet

---

\(^{11}\) In our Walgreens data set, the comparable prices were $6.99 for 24 Tylenol Sinus tablets, $4.99 for 24
Extra Tylenol tablets, and $6.79 for 24 Sudafed. Thus, the price of the branded combination product was
only $0.20 higher than the stand alone Sudafed product. For the Walgreens brands, the prices were $2.99
for 24 tablets of extra strength acetaminophen and $3.49 for 24 maximum strength pseudoephedrine
hydrochloride tablets. While we did not observe a Walgreens version that combined just these two active
ingredients, we did observe a package of 24 tablets with these two ingredients and 25 milligrams of the
antihistimine, Diphenhydramine HCl. The price was $3.99.
packages, the sum of the prices per pill would be more than $0.49/tablet. On a per-pill basis, the price of the bundled product was 64 percent of the price of the components. For the store-brand versions, the per-pill price of the bundled product was less than $0.21, which was 21 percent less than $0.27, the sum of the per-pill prices of the two separate products.

The strong stylized fact that emerges from this set of comparisons is that the prices consumers pay for combinations of medicines—both branded and store-brand—are substantially less than the prices they would pay to buy the same active ingredients as separate medicines. Of course, consumers who want all the components of the combination medicines likely get convenience as well as the lower price.

2. Pricing of Different Dosages

The phenomenon of lower prices for combining the same active ingredient into fewer pills and distinct packages that we observed with combination drugs applies to different doses of the same medicine.

a) Pain Relievers

Tylenol comes in three dosage forms for adults: Regular Strength (325 mg/tablet), Extra Strength (500 mg/tablet), and Arthritis Strength (650 mg/tablet). In a sense, each Arthritis Strength tablet is a bundle of two Regular Strength tablets. As a result, buying two packages of, say, 100 Regular Strength Tylenol rather than one package of 100 Extra

---

12 The price we observed for 24 Advil was $4.99. As reported in note 11, we observed a price of $6.79 at Walgreens for a package of 24 Sudafed.

13 The Walgreens products are WalProfem tablets (ibuprofen), WalPhed (pseudoephedrine hydrochloride) and WalProfem Cold & Sinus. The prices we observed were $4.29 for 20 WalProfem Cold & Sinus Tablets, $2.99 for 24 WalProfem tablets, and $3.49 for 24 WalPhed tablets.

14 It also comes in junior and children’s doses.
Strength Tylenol is analogous to buying Tylenol and Sudafed separately rather than in "sinus tablet" form.

Table 2 presents prices we observed that reveal the economies of combining products as well as the general pricing structure for Tylenol. First, note that in the two cases in which the number of tablets is held constant (50 and 100), the incremental price of the higher levels of extra ingredients is small. At the 50-tablet size, the arthritis strength contains 30 percent more active ingredient for an incremental price of only $0.20, or 2.8 percent. At the 100-tablet size, the Arthritis Strength price is 10 percent higher than the Extra Strength price. In turn, Extra Strength contains approximately 50 percent more active ingredient than regular strength for an incremental price of $0.60 or 6.4 percent. The comparison that most corresponds to the bundling comparison in the previous section is between purchasing one package of 100 Arthritis Strength tablets and two packages of 100 Regular Strength Tablets. The amount of active ingredient is the same, but buying two packages of Regular Strength entails two packages rather than one and twice as many tablets. As Table 2 indicates, the price of the one Arthritis Strength package is $10.99 while the price of two Regular Strength packages is $18.78.\textsuperscript{15}

Table 2. Prices for Different Tylenol Dosages

<table>
<thead>
<tr>
<th>Number</th>
<th>Regular Strength (325 mg)</th>
<th>Extra Strength (500 mg)</th>
<th>Arthritis Strength (650 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>$7.19</td>
<td>$7.39</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>$7.89</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>$9.39</td>
<td>$9.99</td>
<td>$10.99</td>
</tr>
<tr>
<td>150</td>
<td>$14.29</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Prices observed at Walgreens at 757 N. Michigan Ave. in Chicago on April 3, 2003.

\textsuperscript{15} Note further that a package of 60 Extra Strength Tylenol has about the same active ingredient as 100 Regular Strength and costs $1.50 less.
Table 3 shows similar data for Walgreens’ acetaminophen. Here, the evidence is more mixed. The clean comparison that is comparable to the cold medicines is the 100-tablet size. The total price of two packages of Regular Strength acetaminophen is $9.98, which is about 25 percent more than the $7.99 price of a single package of Arthritis Strength. However, it is not universally true that the per-milligram price of the arthritis strength is lower than the per-milligram price of the others.\textsuperscript{16}

<table>
<thead>
<tr>
<th>Number</th>
<th>Regular Strength (325 mg)</th>
<th>Extra Strength (500 mg)</th>
<th>Arthritis Strength (650 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>$2.99</td>
<td>$3.99</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td></td>
<td>$5.49</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>$3.99</td>
<td>$3.99</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>$4.99</td>
<td>$5.99</td>
<td>$7.99</td>
</tr>
<tr>
<td>175</td>
<td></td>
<td>$7.99</td>
<td></td>
</tr>
<tr>
<td>250</td>
<td>$8.99</td>
<td>$13.99</td>
<td></td>
</tr>
<tr>
<td>500</td>
<td>$11.99</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Prices observed at Walgreens at 757 N. Michigan Ave. in Chicago on April 3, 2003.

\textsuperscript{16} All but one of the prices in Table 3 are $0.01 less than an even dollar, with the other being $0.01 less than an integral multiple of $0.50. This feature of the pricing could be part of the explanation for why the price of Arthritis Strength does not show evidence of bundling efficiencies. For example, a price of $3.49 for the package of 24 might not be sufficient to cover the incremental cost. Also, as we will discuss further below, if demand for this package size of Arthritis Strength is sufficiently low, then a higher margin might be needed to cover the fixed cost of the shelf space.
b) Decongestants

Pseudoephedrine hydrochloride comes in three dosage forms. “Maximum Strength” contains 30 mg per tablet. The “12-hour version” contains 120 mg per tablet and the “24-hour version” contains 240 mg per tablet. Table 4 lists the prices that we observed for different package sizes and dosage forms of Sudafed, Contac (another brand of pseudoephedrine hydrochloride) and Walgreens pseudoephedrine hydrochloride. Table 4 provides one clean comparison that is analogous to the bundling analysis above. The price of one package of ten 24-hour Sudafed tablets is $9.99, whereas the sum of the prices of two packages of ten 12-hour Sudafed tablets is $12.98. Note further that the price of five 24-hour Sudafed tablets is somewhat less than the price of ten 12-hour tablets and that the price of ten 24-hour Sudafed tablets is somewhat less than the price of twenty 12-hour tablets. The differences are not large. However, the obvious source of cost savings from the 24-hour version concerns placing the medicine into tablets. Since the absolute difference in the number of tablets is small, one would not expect large cost differences.\(^{17}\)

<table>
<thead>
<tr>
<th>Number of Tablets</th>
<th>30 mg/tablet</th>
<th>120 mg/tablet</th>
<th>240 mg/tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sudafed</td>
<td>Walgreens</td>
<td>Contac</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>$6.79</td>
<td>$3.49</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>$14.99</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Prices observed at Walgreens at 757 N. Michigan Ave. in Chicago on April 3, 2003.

\(^{17}\) Note that one odd feature of the table is that the price of 96 Walgreens Maximum Strength tablets is more than double the price of a package with half the number of tablets. That price is the exception, however. In general, the price per tablet is lower for larger package sizes.
3. Package Size Effects

The third empirical regularity we document concerns package size, which is another form of bundling. A package of 200 tablets is a bundle of two packages of 100 tablets. In addition to providing evidence of another source of gains from bundling, evidence on the prices of different package sizes will yield insights into the fixed costs of product offerings.

Pain relief medications provide better evidence about package size effects than do decongestants or antihistamines because they come in a broader range of packages. Figure 1 presents the data on extra strength acetaminophen and Figure 2 presents the data on ibuprofen. Each graph contains two series, one for branded versions and one for the Walgreens product. All four of the series are concave and would appear to have a positive intercept.

Figure 1. Extra Strength Acetaminophen Prices
Figure 2. Extra Strength Acetaminophen Prices

B. Regression Results

With the above results in hand, we now seek to estimate a single regression equation to characterize the gains consumers realize from purchasing bundled products. The data set we collected had 305 observations. However, these included a variety of dosage forms, such as tablets, liquids, and liqui-gels. To avoid any misspecification from how we treat dosage forms, we restricted attention to tablets or delivery forms typically priced the same as tablets.\textsuperscript{18} This eliminated a large fraction of the medicines with cough suppressants. Also, the variety of active ingredients to treat coughs is substantially greater than the variety of decongestants, antihistamines, and pain relievers; and we were

\textsuperscript{18} This filter excluded any medicines in liquid or packet form as well as “liqui-gels,” which typically sell for a premium. It includes caplets.
concerned that we would be unable to get reliable estimates of how each cough suppressant is priced. As a result, we excluded cough medicines. More precisely, we restricted attention to tablets in which the active ingredients were limited to the pain relievers acetaminophen and ibuprofen, the decongestant pseudoephedrine hydrochloride, and the antihistamines chlorpheniramine maleate and diphenhydramine HCl.\textsuperscript{19} This left us with 112 observations.

In order to capture brand effects and the non-linearities in package size documented above, we chose the following specification:

\[
P_i = b_0 + b_1 T_i + b_2 T_i^2 + b_3 T_i B_i + b_4 T_i B_i^2 + \sum_{j=1}^{N} c_j Z_{ij}
\]

where:

- \(P_i\) is the price of package \(i\)
- \(T_i\) is the number of tablets in package \(i\)
- \(B_i\) is a brand name dummy for package \(i\)
- \(Z_{ij}\) is the amount of ingredient \(j\) in package \(i\)

The presence of a brand premium raises issues for the effect of bundling in this case. To see the general issue, consider Table 1. For the branded products, the bundle discount is computed as the price of Tylenol Sinus (or Sudafed Sinus Headache) with the sum of the prices of Tylenol Extra Strength and Sudafed Maximum Strength. Both of the prices of the component products include a brand premium.\textsuperscript{20} Unless the price of the

\textsuperscript{19} Thus, we excluded medicines with cough suppressants. The products we observed contained a much greater variety of cough suppressants than of the other types of ingredients, and we were concerned that we did not have sufficient data to estimate with much accuracy the price effects of each cough suppressant.

\textsuperscript{20} The fact that Tylenol is a Johnson & Johnson brand while Sudafed is a Pfizer brand is of interest, but a similar issue would arise if the same company owned both.
bundled product includes a double brand premium, then part of the bundle discount reflects a brand premium effect.\textsuperscript{21}

Our specification allows the brand premium to be a quadratic function of the number of tablets. While this functional form allows for some flexibility in estimating how companies impose a brand premium, it does not allow the brand premium to be a function of the number of active ingredients. Neither does it allow for the brand premium to depend on the volume of active ingredient per tablet.\textsuperscript{22} We ran regressions in which the brand premium could depend on the number of active ingredients. They provided no evidence that bundled, branded products command a higher (absolute) premium than do unbundled ones.\textsuperscript{23}

Our estimated equation is:

$$R_i = 2.31 + 0.029 T_i - 3.3 \times 10^{-5} T_i^2 + 0.63 B_i + 0.054 T_i B_i - 1.23 \times 10^{-4} T_i^2 B_i$$

$$+ 0.014 B_i + 0.012 AC_i + 0.065 PH_i + 0.035 CM_i + 0.042 DI_i$$

$$s = 1.24, R^2 = 0.91, F = 132.31^*, N = 112$$

(Note: Values in parenthesis are absolute values of asymptotic t-statistics based on heteroskedasticity-consistent standard errors. * denotes significance at 1 percent (two-tailed) level.)

\textsuperscript{21} As we will see, the brand effect accounts for a substantial piece of the bundle discount in this case. Exactly how to interpret this effect would require a better understanding of the source of brand premia than one can currently get from the economics literature. The branding effect could easily be the subject of an entire other paper. In this paper, we merely document the effect and leave its explanation as a potential avenue for future research.

\textsuperscript{22} If, for example, one compares the three different strengths of Tylenol described above, it would be of interest to estimate whether the brand premium depends on the number of tablets or on the amount of acetaminophen.

\textsuperscript{23} We believe that the branding effect of bundling is potentially of great interest in understanding branding, but we do not pursue it in more detail here because we suspect that it is not a common effect of bundling.
Where:

\[ \text{IB}_i = \text{ibuprofen in package } i \text{ in units of 200 mgs} \]
\[ \text{AC}_i = \text{acetaminophen in package } i \text{ in units of 500 mgs} \]
\[ \text{PH}_i = \text{pseudoephedrine hydrochloride in package } i \text{ in units of 30 mgs} \]
\[ \text{CM}_i = \text{chlorpheneramine maleate in package } i \text{ in units of 2 mgs} \]
\[ \text{DI}_i = \text{diphenhydramine in package } i \text{ in units of 25 mgs} \]

The coefficients on the active ingredients are all positive. The coefficients on the amount of acetaminophen and on ibuprofen are small and imprecisely determined. That they are small makes sense. The price of both bulk acetaminophen and bulk ibuprofen is approximately $8/kg,\textsuperscript{24} which would contribute $0.004 per 500 mg acetaminophen tablet and $0.0016 per 200 mg ibuprofen tablet.

These regressions reveal three primary sources of gains to consumers from buying bundled products. The first is the intercept term of $2.31, which is highly statistically significant. The purchaser of the bundled product pays one fixed component in the price term. Purchasers of the two separate products would pay two. The second component is associated with the number of tablets. It is \(0.029 \times T_i - 3.3 \times 10^{-5} \times T_i^2\). Again, purchasers of the bundled product pay this component once. Purchasers of two separate products would pay it twice. This component of the savings comes to $0.67 for 24-tablet packages and $1.29 for 48-tablet packages. Thus, the cost-based savings absent of brand effects is $2.98 for 24 tablet packages and $3.60 for 48 tablet packages. The third component

\textsuperscript{24} See http://www.the-innovation-group.com/ChemProfiles/Acetaminophen.htm and www.tulika.com/exportprices.htm
applies only to purchasers of branded products. It is given by $0.63 + 0.54 T_i - 0.00012 T_i^2$. It amounts to $1.84$ and $2.92$ for 24-tablet and 48-tablet packages, respectively.\(^{25}\)

III. Modeling the Bundle Discount

In Evans and Salinger (2004a), we present a cost-based model that serves as a unified framework for understanding bundling and tying under competition. In this section, we apply that framework to model the bundle discount we have observed.\(^{26}\)

The essential features of the framework are:

1. There are two products, A and B, that can be sold separately or bundled;
2. Some customers want A, some want B, and some want both;
3. The marginal cost of the bundle might be lower than the sum of the marginal costs of the components;
4. There is a fixed cost of each product offering;
5. Markets are perfectly contestable, which implies that prices equal average cost; and
6. The prices for the goods offered in the market are sustainable.

The first three of these seem readily applicable to this case. The different medications can be (and are) sold both separately and in combination. To use the example in Table 1, some people have a headache and want just acetaminophen. Some people have a cold and want just a decongestant. Some have a sinus headache and want both. Because of savings in packaging, making tablets, and transactions expense, the marginal cost of the bundled product is less than the sum of the marginal costs of the unbundled items.

\(^{25}\) These estimates are for the savings from buying a bundled medicine with two active ingredients as compared with buying the components separately. The effect would be twice as large for products with three active ingredients as compared with buying all three separately.

\(^{26}\) In broad terms, either the bundle discount reflects cost differences or it is price discrimination. See Evans and Salinger (2004b) for a discussion of why the discount is not entirely (or even primarily) price discrimination.
Assumption 3 implies that, without some constraint on the products offered, there is an advantage to having the bundle available in addition to the separate components. The bundle makes it possible to satisfy the demand of people who want both components at a lower cost and, therefore, price. In practice, another efficiency of bundling is that it provides convenience. If so, consumers who want both components would be willing to pay a convenience premium to buy them in bundled form. It would be trivial to extend the model to allow for a convenience premium. We do not do so here for two reasons. First, we want to keep the model simple, and marginal cost savings are sufficient to make those who want both components prefer to buy them in bundled form. Second, under competition, the convenience value would not be reflected in prices. Measuring it would require more precise estimates of demand than we attempt here.

The fourth assumption is necessary to capture the possibility of tying. Tying, as an economic matter, occurs when the two products are sold in bundled form and at least one of the products is not available separately. As such, it represents a limitation on the products that are offered. To make sense of this limitation when there are some customers who would like the component that is not offered, there needs to be some product-specific scale economy. The simplest way to model these scale economies is to assume a fixed cost of each product offering.

Tying is a prevalent practice under competition. Indeed, our objective in formulating the model was to understand tying under competition. Given that scale economies are necessary to understand tying, however, one cannot assume perfect competition. The contestability assumption is a way of incorporating competition into a model when scale economies are present. Like any model, it should be viewed as an
approximation. The key implication of a contestability model is that prices are determined primarily by costs with the underlying elasticity of demand playing at most a secondary role. This perspective is in distinct contrast to price discrimination models. In evaluating whether contestability is a reasonable approximation, we need to consider whether the threat of entry is the primary constraint on the extent to which prices can exceed costs. Given the substantial number of large companies that would seem to have the capability to produce and market any one of these products, that assumption strikes us as being reasonable.

In this case, tying does not occur. In the Evans-Salinger model, however, mixed bundling is a possible outcome, so the absence of tying is not a reason to reject the model. Moreover, fixed costs of product offerings are likely present in this case even if they are not sufficient to result in tying. Each additional stock keeping unit (sku) imposes a cost on a retailer as it must order the product, maintain inventories, and so on. In addition, each distinct product sold by a retailer must occupy a shelf slot. The cost of these slots is an example of what accountants refer to as “semi-fixed” or “step” costs. They are not fixed with respect to all levels of output, but they are incurred in discrete units (or “steps”). Whether or not such costs should be deemed primarily fixed or primarily marginal depends on the size of the steps relative to total demand. We do not have the information one would need to determine whether shelf space should be

---

27 This comment requires some qualification. To take one example, Johnson & Johnson sells acetaminophen alone and acetaminophen in combination with pseudoephedrine HCl. It does not sell pseudoephedrine HCl alone. While this is technically tying from the standpoint of the company, the market outcome does not entail tying. One can purchase pseudoephedrine HCl. Moreover, because Johnson & Johnson does sell Tylenol without any additional active ingredients, its tying is not the sort that could raise antitrust concerns.

28 The model assumes that consumers who want just one component are willing to buy it as part of the bundle. In economics terminology, we assume free disposal. That plainly does not apply to this case. Many
considered a fixed or marginal expense, but it is at least plausible that it is more nearly fixed.\textsuperscript{29}

In the simplest version\textsuperscript{30} of the model, let $X_1$ be the number of people who want just good 1, $X_2$ be the people who want just good 2, and $X_B$ be the number of people who want both. Let $F$ be the fixed cost of a product offering, $c_1$ and $c_2$ be the marginal cost of goods 1 and 2, respectively, and $c_B$ be the marginal cost of the bundle with $c_B \leq c_1 + c_2$.

Letting $p_1$, $p_2$, and $p_B$ be the prices of goods 1 and 2 and of the bundle, then the contestable prices are:

$$(3) \quad p_i = c_i + \frac{F}{X_i} \quad i \in \{1, 2, B\}$$

and the discount for the bundle (DB) is given by:

$$(4) \quad DB \equiv p_1 + p_2 - p_B = c_1 + c_2 - c_B + \frac{F}{X_1} + \frac{F}{X_2} - \frac{F}{X_B}$$

As equation (4) makes clear, there are two possible sources of the bundle discount. One is marginal cost savings, $c_1 + c_2 - c_B$. The other concerns fixed costs. A customer who buys the two components separately contributes to two fixed costs; the purchaser of the bundled product only contributes to one.

Without knowing $X_1$, $X_2$, and $X_B$, we cannot be sure that the bundle discount is attributable at all to fixed costs. As a practical matter, however, it likely is. To cover its

\textsuperscript{29} One relevant piece of information is the number of shelf slots devoted to an item. In grocery stores, it is common to observe multiple slots devoted to two-liter bottles of Coca-Cola, and the number of slots increases when Coca-Cola is a sale item. In that case, the shelf space should be treated as a marginal cost. When just one shelf slot is devoted to an item, there is a stronger case for treating shelf space as a fixed cost.

\textsuperscript{30} In this version, demand by each group is treated as being perfectly inelastic within the range of prices that might prevail. See the appendix to Evans and Salinger (2004a) for an extension to price-sensitive demand.
costs, a retailer must “mark up” the prices of the items it sells. Unless the retail mark-up on the bundled item is at least the sum of its mark-ups on the components—and there is no reason to suppose that it is—then part of the customer savings reflects retail mark-ups.

A key result in Evans and Salinger (2004a) is that mixed bundling can occur even if it is not the set of offerings that minimizes total costs. Under mixed bundling, there has to be a bundle discount, but the private savings from the bundle discount do not necessarily represent social savings. If we let SB be the cost savings from offering the bundle (stated on a per-customer basis to aid comparability with the bundle discount), then:

\[ SB = c_1 + c_2 - c_B - \frac{F}{X_B} = DB - \frac{F}{X_1} - \frac{F}{X_2}. \]

The first three terms of (5), which reflect marginal costs, are identical to (4). With the marginal costs, private savings reflect social savings. The last term of (5) is also the last term of (4). There is a social fixed cost of offering the bundle that must be subtracted from the marginal cost savings. In a contestable market, purchasers of the bundle bear this cost as well. The difference between (4) and (5) comes from the two terms in (4) that reflect the average fixed costs of the two component goods. If those who want both components were to buy them separately, the prices they would pay would reflect these fixed costs. When they buy the bundle instead, they get a private benefit from not contributing to those fixed costs, but there is no corresponding social benefit because the fixed costs of the components are not reduced.

---

31 Otherwise, consumers who want both components would not buy the bundle.
32 SB represents the savings from offering the bundle given that goods 1 and 2 are also offered.
The last part of equation (5) provides a simple approach to inferring the cost savings from the bundle (under mixed bundling) from the bundle discount. It says that the cost savings (per consumer of the bundle) are the bundle discount minus the average fixed cost portion of the prices of the two separate goods.

The following pair of examples illustrates the point:

Example 1: \( c_1 = c_2 = 2, c_B = 2.9, F = 0, X_1 = X_2 = X_B = 100 \)

Example 2: \( c_1 = c_2 = 1, c_B = 1.9, F = 100, X_1 = X_2 = X_B = 100 \)

In both cases, the unique sustainable outcome is mixed bundling with \( p_1 = p_2 = 2 \) and \( p_B = 2.9 \). The bundle discount is substantial. In example 1, the bundle discount entirely reflects social savings. The total cost of meeting demand with mixed bundling is 690. The cost of meeting demand with components selling would be 800, or 110 more. In example 2, the total cost of meeting demand with mixed bundling is also 690, just as in example 1. In contrast to example 1, however, the total cost of meeting demand with components selling would be only 600. Unless the bundled product provides convenience for the customers who want both items, the mixed bundling would be inefficient despite the substantial bundle discount.

---

33 This point should be obvious for example 1. For example 2, the prices under pure components selling would be $1.50 (calculated as \( 1 + 100/200 \)) for each item. Customers who buy both pay a total of 3. This outcome is not sustainable because it is susceptible to entry with the bundle at a price of 2.9. Similarly, pure bundling is not sustainable. The price under pure bundling would be 1.9 + 100/300 ≈ 3.23. That price is not sustainable because an entrant could break even selling either component at a price of 3.

34 In example 2, there are some marginal cost savings from bundling. If there were no marginal cost savings from bundling, then mixed bundling would still be sustainable (and inefficient), but it would not be the unique sustainable outcome. Components selling would be sustainable as well. Mixed bundling can be the unique sustainable outcome with no marginal cost savings from bundling if \( X_B \) is greater than the geometric mean of \( X_1 \) and \( X_2 \). For a more complete explanation, see Evans and Salinger (2004a).
A similar point applies to the individual components. Under mixed bundling, the price of each component has to be less than the price of the bundle, but that does not imply that offering the separate good lowers costs. If we let $DC_i$ and $SC_i$ be the discount and cost savings (per customer of good $i$) of offering good $i$ (given that the bundle is offered), we have:

$$DC_i \equiv p_i - p_B = c_B - c_i + \frac{F}{X_B} - \frac{F}{X_i}$$

(6)

$$SC_i = c_B - c_i - \frac{F}{X_i} = DC_i - \frac{F}{X_B}$$

(7)

Equation (7) says that to infer the cost savings from having a component available separately, one must subtract the average fixed cost component of the price of the bundled good from the component discount.

Referring back to our pricing regression, the bundle discount has three components: the intercept, the coefficients on the tablet variables, and the coefficients on the brand-name variables. As noted above, we focus on the first two. The estimated equation distinguishes between price components that are fixed and variable with respect to package size. Within our model, however, the key distinction is whether or not the costs are fixed or marginal with respect to a customer. The cost of placing active ingredients into tablets and, to some extent, the cost of the package itself, are examples of costs that are marginal with respect to both package size and to the customer. To the extent that package costs rise less than proportionately with the number of tablets,

---

35 Another simplifying assumption of our model is that consumers who want just one of the goods get no utility or disutility from the other good. As a result, they view the bundle as a perfect substitute for the good they want. That assumption does not apply to our application, since, for example, many consumers who want just a pain reliever would prefer not to have to take a decongestant as well. Just as it would be easy to incorporate a convenience value for the bundle in the model, we could also assume that consumers who want just one component are willing to pay a premium not to have it bundled with the other.
however, then part of packaging cost would be reflected in our intercept term. Even though this component is fixed with respect to package size, it is variable with respect to the customer. Another example of this kind of cost is the cost of the time it takes a clerk to process a transaction. Finally, some costs are fixed both with respect to the customer and to the size of the package. The costs of having an additional SKU and, to a large extent, the cost of shelf space are examples.

IV. Decomposing Fixed and Marginal Cost Effects with Package Size Pricing Regularities

We now show how to use the package-size regularities documented in Section II to decompose the bundle and component discounts into marginal cost and fixed cost components. This decomposition will then allow us to measure the (possibly negative) cost savings (per customer) from each product.

1. Theory

The key to understanding the size of the the product-specific fixed costs is to observe products that could conceivably exist but do not. In the cases we have considered, product tying does not occur. Among the products sold in bundled form that we have

36 Our argument that the packaging cost is reflected at least partially in the intercept term does not require that the packaging cost equation literally has a positive intercept. If we observed packaging costs directly, our estimates of the marginal cost savings from bundling would be based on the cost of a package of a given size, such as 24 tablets or 48 tablets. Taken, literally, the intercept reflects the cost of a 0-tablet package, which is irrelevant for computing the gains from bundling. Given our choice of a quadratic functional form, however, the cost of a package of a particular size would be reflected in part in the intercept.

37 It is possible that some costs might be variable with respect to package size but fixed with respect to the customer. This could happen if, for example, larger packages require more shelf space. Our procedure for estimating the component of price that covers fixed costs ignores this possibility.

considered, all the component medicines are available separately. Rather than looking to products that do not exist, we look to package sizes that are not offered. The price-package size relationships presented in Figures 1 and 2 provide evidence of economies of package size. As a consequence, customers who want a large quantity are better off buying one large package than several smaller ones. However, not all possible package sizes are offered. For example, the Walgreens in question sold Extra Strength Tylenol in packages of 24, 100, 150, 200, and 225. It did not, however, sell packages of 175. There does not seem to be any reason to suppose that there were no customers who would most prefer to buy 175. Such a customer must choose between buying a package of 200 and wasting 25 of them or buying a package of 150 and supplementing the package of 150 with, say, another package of 24.\textsuperscript{39}

Given the economies of package size, neither of these solutions would give the customer as good a price as he would get if a package of 175 were available on the market.

To estimate the cost factor that prevents the package of 175 from being introduced, we need to introduce some theory that extends the contestability analysis from our previous paper. The general approach is to view the set of products offered and their prices as a sustainable market outcome, which means that entry with another product, (which in this case is a different package size), is not profitable. Let \(Q_i\), \(Y_i\), and \(P_i\) be the package size, number of purchasers, and price of package \(i\) for \(i = 1\) or \(2\) with \(Q_1 < Q_2\). Let \(C(.)\) be the marginal cost of selling a package of a particular size to an extra customer. Then, the contestability result that price equals average cost implies:

\[
P(Q_i) = \frac{F}{Y_i} + C(Q_i)
\]

\textsuperscript{39} This choice would, of course, leave the consumer one pill short of his desired quantity.
Let $\bar{Q}$ be the average of $Q_1$ and $Q_2$, and assume that if $\bar{Q}$ were offered at a lower price, half the people who buy $Q_2$ would buy $\bar{Q}$ instead. The price at which it could be offered would be:

$$P(\bar{Q}) = \frac{2F}{Y_2} + C(\bar{Q})$$

We now need to make the simplifying assumptions that $Q_1$ and $Q_2$ are close enough to each other that a linear approximation of the marginal cost function is reasonable and that $Y_1 = Y_2$. With these additional assumptions, it is straightforward to show that the condition that makes it impossible to offer the package size half way between $Q_1$ and $Q_2$ is:

$$\frac{F}{Y_2} > \frac{P_2 - P_1}{2}$$

2. Results

The left-hand side of (10) is the component of the price that goes to covering the fixed cost. Each successive pair of package sizes yields an estimate. Figure 3 shows a histogram of our estimates of the lower bounds of the fixed costs taken from the data underlying Figures 1 and 2. The mean value is $1.33$, the median is $1.20$, and the modal range is $1.00$ to $1.50$. Taking the median as our estimate, we estimate that $1.20$ of each package price represents a contribution to fixed costs.

---

40 This condition only insures that the existing offering is sustainable with respect to entry half way between two package sizes that are offered. More generally, one might impose the condition that the offering be sustainable with respect to all possible intermediate package sizes. In doing so, however, one would probably not make our simplifying assumptions about marginal cost and demand.
In Section II, we estimated a cost-based savings\textsuperscript{41} of $2.98 and $3.60 for 24-count and 48-count packages of tablets with two active ingredients. Given our estimate of $1.20 as the part that reflects a contribution to fixed costs, the implied marginal cost savings are $1.78 and $2.40. Using equation (5), we estimate that the cost savings per customer from the bundled products are $0.58 and $1.20, respectively.

Both the private and net savings would be larger for tablets that combine three active ingredients. The private savings are twice as large, so they are $5.96, which reflects $3.56 in marginal cost savings and $2.40 in average fixed cost. From the

\textsuperscript{41} By cost-based savings, we mean those not related to branding effects.
marginal cost savings of $3.56, which represents a social benefit, we must subtract the $1.20 average fixed cost of the additional offering. The net cost savings are $2.36.

The gains from bundling would also be larger for larger packages. For example, for packages of 48 tablets, our regression equation implies private gains of $3.60 and $7.20 for tablets that combine two ingredients and three ingredients, respectively. The net effect on costs would then be savings of $1.20 and $3.60 for the bundled products.\(^{42}\)

We can also use equation (8) to estimate whether there are cost savings from offering the stand-alone products. Consider again the example in Table 1. The regression results indicate that for people who want just acetaminophen, the marginal cost of buying acetaminophen bundled with pseudoephedrine hydrochloride would be $0.065 \cdot 24 = $1.56. As this exceeds our estimate of the average fixed cost of $1.20, we estimate the cost savings from having the stand-alone acetaminophen product to be $0.36. For consumers who want just pseudoephedrine hydrochloride, the regression results imply that the marginal cost of buying it bundled with acetaminophen would be $0.012 \cdot 24 = $0.29. As this incremental cost is less than the average fixed cost, it would lower costs not to offer the 24-tablet package of just pseudoephendrine hydrochloride. In other words, tying would lower costs.\(^{43}\)

V. Summary and Conclusions

As we discuss in greater detail in Evans and Salinger (2004b), bundling and tying law is unsettled in both the United States and Europe. We believe that policy makers

\(^{42}\) The calculations are $3.60 – 2 \cdot $1.20 = $1.20 and $7.20 – 3 \cdot $1.20 = $3.60.

\(^{43}\) Assuming that the groups that want just pseudoephedrine HCl and that want the bundled product are of equal size, tying would also be sustainable. By pricing the bundled product to attract the group that wants
would welcome insights from the economics literature on how to formulate a more sensible policy. To date, however, that literature has been largely theoretical. If there is to be an empirical literature on bundling and tying that informs policy, it must be based on some underlying theory. We believe that the framework we have used in this paper will prove to be superior to competing frameworks both because it is more tractable and because it more nearly captures the essence of most of the bundling and tying that occurs in practice.

When we apply our framework to over-the-counter pain relief and cold medicines, we find a substantial bundle discount, which we interpreted within a cost-based model of bundling and tying under competition. The model highlights the importance of distinguishing between the effects of fixed and marginal costs. Either can give rise to a bundle discount, but whether mixed bundling is the set of product offerings that minimizes the cost of satisfying different types of customers depends critically on the relative contribution of each effect.

---

just the decongestant, the average fixed costs could be reduced from $1.20 to $0.60. This $0.60 price reduction would more than offset the $0.29 marginal cost associated with the extra active ingredient. An exception is Crawford (2004).
References


1237 M. Hashem Pesaran, Davide Pettenuzzo, and Allan Timmermann, Forecasting Time Series Subject to Multiple Structural Breaks, July 2004


1239 Eckhard Janeba, Moral Federalism, July 2004


1241 Hans Jarle Kind, Karen Helene Midelfart, Guttorm Schjelderup, Corporate Tax Systems, Multinational Enterprises, and Economic Integration, July 2004


1243 Wolfgang Eggert and Alfons J. Weichenrieder, On the Economics of Bottle Deposits, July 2004

1244 Sören Blomquist and Vidar Christiansen, Taxation and Heterogeneous Preferences, July 2004

1245 Rafael Lalive and Alois Stutzer, Approval of Equal Rights and Gender Differences in Well-Being, July 2004

1246 Paolo M. Panteghini, Wide vs. Narrow Tax Bases under Optimal Investment Timing, July 2004

1247 Marika Karanassou, Hector Sala, and Dennis J. Snower, Unemployment in the European Union: Institutions, Prices, and Growth, July 2004


1249 Francesco Giavazzi and Guido Tabellini, Economic and Political Liberalizations, July 2004

1250 Yin-Wong Cheung and Jude Yuen, An Output Perspective on a Northeast Asia Currency Union, August 2004

1251 Ralf Elsas, Frank Heinemann, and Marcel Tyrell, Multiple but Asymmetric Bank Financing: The Case of Relationship Lending, August 2004
1252 Steinar Holden, Wage Formation under Low Inflation, August 2004


1254 Klaus Wälde and Pia Weiß, International Competition, Slim Firms and Wage Inequality, August 2004


1256 Guido Tabellini, The Role of the State in Economic Development, August 2004

1257 François Larmande and Jean-Pierre Ponssard, EVA and the Controllability-congruence Trade-off: An Empirical Investigation, August 2004

1258 Vesa Kanniainen and Jenni Pääkkönen, Anonymous Money, Moral Sentiments and Welfare, August 2004

1259 Panu Poutvaara and Andreas Wagener, Why is the Public Sector More Labor-Intensive? A Distortionary Tax Argument, August 2004

1260 Lars P. Feld and Stefan Voigt, Making Judges Independent – Some Proposals Regarding the Judiciary, August 2004

1261 Joop Hartog, Hans van Ophem, and Simona Maria Bajdechi, How Risky is Investment in Human Capital?, August 2004

1262 Thomas Eichner and Rüdiger Pethig, Efficient Nonanthropocentric Nature Protection, August 2004

1263 David-Jan Jansen and Jakob de Haan, Look Who’s Talking: ECB Communication during the First Years of EMU, August 2004

1264 David F. Bradford, The X Tax in the World Economy, August 2004

1265 Hans-Werner Sinn, Migration, Social Standards and Replacement Incomes. How to Protect Low-income Workers in the Industrialized Countries against the Forces of Globalization and Market Integration, August 2004

1266 Wolfgang Leininger, Fending off one Means Fending off all: Evolutionary Stability in Submodular Games, August 2004

1267 Antoine Bommier and Bertrand Villeneuve, Risk Aversion and the Value of Risk to Life, September 2004

1268 Harrie A. A. Verbon and Lex Meijdam, Too Many Migrants, Too Few Services: A Model of Decision-making on Immigration and Integration with Cultural Distance, September 2004
Thomas Eichner and Rüdiger Pethig, Economic Land Use, Ecosystem Services and Microfounded Species Dynamics, September 2004

Federico Revelli, Performance Rating and Yardstick Competition in Social Service Provision, September 2004

Gerhard O. Orosel and Klaus G. Zauner, Vertical Product Differentiation When Quality is Unobservable to Buyers, September 2004

Christoph Böhringer, Stefan Boeters, and Michael Feil, Taxation and Unemployment: An Applied General Equilibrium Approach, September 2004


Tomer Blumkin and Volker Grossmann, Ideological Polarization, Sticky Information, and Policy Reforms, September 2004

Katherine Baicker and Nora Gordon, The Effect of Mandated State Education Spending on Total Local Resources, September 2004

Gabriel J. Felbermayr and Wilhelm Kohler, Exploring the Intensive and Extensive Margins of World Trade, September 2004

John Burbidge, Katherine Cuff and John Leach, Capital Tax Competition with Heterogeneous Firms and Agglomeration Effects, September 2004

Joern-Steffen Pischke, Labor Market Institutions, Wages and Investment, September 2004

Josef Falkinger and Volker Grossmann, Institutions and Development: The Interaction between Trade Regime and Political System, September 2004

Paolo Surico, Inflation Targeting and Nonlinear Policy Rules: The Case of Asymmetric Preferences, September 2004

Ayal Kimhi, Growth, Inequality and Labor Markets in LDCs: A Survey, September 2004

Robert Dur and Amihai Glazer, Optimal Incentive Contracts for a Worker who Envies his Boss, September 2004

Klaus Abberger, Nonparametric Regression and the Detection of Turning Points in the Ifo Business Climate, September 2004

Werner Güth and Rupert Sausgruber, Tax Morale and Optimal Taxation, September 2004
1285 Luis H. R. Alvarez and Erkki Koskela, Does Risk Aversion Accelerate Optimal Forest Rotation under Uncertainty?, September 2004

1286 Giorgio Brunello and Maria De Paola, Market Failures and the Under-Provision of Training, September 2004

1287 Sanjeev Goyal, Marco van der Leij and José Luis Moraga-González, Economics: An Emerging Small World?, September 2004

1288 Sandro Maffei, Nikolai Raabe and Heinrich W. Ursprung, Political Repression and Child Labor: Theory and Empirical Evidence, September 2004

1289 Georg Götz and Klaus Gugler, Market Concentration and Product Variety under Spatial Competition: Evidence from Retail Gasoline, September 2004

1290 Jonathan Temple and Ludger Wößmann, Dualism and Cross-Country Growth Regressions, September 2004

1291 Ravi Kanbur, Jukka Pirttilä and Matti Tuomala, Non-Welfarist Optimal Taxation and Behavioral Public Economics, October 2004

1292 Maarten C. W. Janssen, José Luis Moraga-González and Matthijs R. Wildenbeest, Consumer Search and Oligopolistic Pricing: An Empirical Investigation, October 2004


1294 Christoph A. Schaltegger and Lars P. Feld, Do Large Cabinets Favor Large Governments? Evidence from Swiss Sub-Federal Jurisdictions, October 2004

1295 Marc-Andreas Mündler, The Existence of Informationally Efficient Markets When Individuals Are Rational, October 2004

1296 Hendrik Jürges, Wolfram F. Richter and Kerstin Schneider, Teacher Quality and Incentives: Theoretical and Empirical Effects of Standards on Teacher Quality, October 2004

1297 David S. Evans and Michael Salinger, An Empirical Analysis of Bundling and Tying: Over-the-Counter Pain Relief and Cold Medicines, October 2004